Wed, May 16, 2012
Tue, May 15, 2012
[ Tue, May 15th 2012 ] - Market Wire
CryoLife to Acquire Hemosphere
Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ] - Market Wire
00 p.m. EDT
Wed, May 2, 2012

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. ca-merrill-lynch-2012-healthcare-conference.html
Published in Health and Fitness on Thursday, May 10th 2012 at 6:42 GMT by Market Wire   Print publication without navigation


Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare... -- TARRYTOWN, N.Y., May 10, 2012 /PRNewswire/ --

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference

[ ]

TARRYTOWN, N.Y., May 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012.  The presentation is scheduled for 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time).  The session may be accessed through the Company's web site, [ www.regeneron.com ], on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST®(rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contact Information:




Manisha Narasimhan, Ph.D.  

Peter Dworkin

Investor Relations 

Corporate Communications                      

914-847-5126  

914-847-7640                      

[ manisha.narasimhan@regeneron.com ]  

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources